Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

待确认 10 由 77 发布于 2025/2/8 14:20:09

DOI:10.1016/S0140-6736(22)00662-6
作者：Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with current standard of ca

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

9小时前

小丹

202502081637448037706.pdf

11小时前

kmao

93f58eb4e5e511efbbf634735aa3bc31.pdf 已驳回

11小时前

坐看云起时

c676182ae5e411efab9b34735aa3bc31.pdf 已驳回

11小时前

Book学术机器人

2025/2/8 14:20:09 未找到该文献，机器人已退出，请等待人工下载

2025/2/8 14:20:09 Book学术AI机器人收到请求，开始寻找文献

2025/2/8 14:20:09 已向机器人发送请求

11小时前

77 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库In-house Test Wafer Reclaim for Fab Cost and Wastage Reduction: MS: Manufacturing for Sustainability